louisakewell, Author at European Medical Journal - Page 71 of 153

EMJ

GRANU FINK®: Effective and Well Tolerable for the Treatment of Mild to Moderate LUTS

Munich, Germany, 12-14 March, 2016: At the 31st Annual European Association of Urology (EAU) Congress the phytomedicine GRANU FINK® Prosta forte 500 mg…

EMJ

Helsinn Presents Quality of Life, Its First Group Sustainability Report

Lugano, Switzerland, March 23, 2016: Helsinn Group is pleased to present its first group sustainability report, Quality of Life, demonstrating that…

EMJ

STELARA® Induced Clinical Response and Remission in Phase 3 Study for the Treatment of Patients with Moderate to Severe Crohn’s Disease Who Had Previously Failed or Were Intolerant to Anti-TNF-Alpha Therapy

STELARA® Induced Clinical Response and Remission in Phase 3 Study for the Treatment of Patients with Moderate to Severe Crohn’s Disease Who Had Previously Failed or Were Intolerant to Anti-TNF-Alpha Therapy

EMJ

Sneaking through Barrier Gaps: Gut Microbiota Imbalance Harms the Liver

March 14, 2016: The potential consequences of gut microbial dysbiosis are not restricted to bowel conditions only. Prominent among the other organs…

EMJ

Gut Profiling: New Biomarkers for Metabolic Diseases

March 11, 2016: For diagnosing or predicting metabolic diseases such as obesity, insulin resistance or type two diabetes (T2D), doctors commonly make use…

EMJ

Treatment Advances and New Centres of Excellence Offer Lifeline to Patients with Inoperable Neuroendocrine Cancers

1 March 2016: A novel drug proven to reduce the risk of disease progression by 79% as well as three new European Centres of Excellence, offer new hope…

EMJ

Precision medicine for metastatic breast cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Janice Tsang, MBBS…

EMJ

First Patients Enrolled and Dosed in the Pivotal Trial of Phase 3 of the Immunotherapy Tedopi® for Advanced Non-Small Cell Lung Cancer

Paris, February 22nd, 2016, 6:30pm – OSE Pharma SA (ISIN: FR0012127173; Mnémo: OSE), an immunooncology company with a specific immunotherapy…

EMJ

Patient Enrolment Completed in US Phase IIb Study of GrassMATAMPL

Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today announces it has completed…

EMJ

Overview of a Phase I study of ONO/GS-4059 in relapsed and refractory mature B-cell malignancies

Martin JS Dyer, MA, DPhil, FRCP, FRCPath from the University of Leicester, Leicester, UK, provides an overview of a Phase I study of ONO/GS-4059, a…